Advertisement

Medicinal Chemistry Research

, Volume 28, Issue 12, pp 2171–2183 | Cite as

Synthesis and cytotoxic activity of 3-amino substituted fusidane triterpenoids

  • Elena V. SalimovaEmail author
  • Elena V. Tret’yakova
  • Lyudmila V. Parfenova
Original Research
  • 99 Downloads

Abstract

New 3-amino substituted derivatives, containing linear, aromatic, and heterocyclic fragments, as well as conjugates with biogenic amines—spermine and spermidine, were synthesized from 3,11-dioxo analogs of fusidic acid and its methyl ester. Antitumor activity of the compounds was studied in vitro towards the 60 cell lines of nine different types of human tumors of the NCI collection. Introduction of pyrrolidine, n-butylamine, benzylamine, and ethylenediamine substituents into the molecules were found to provide a pronounced selective effect on five cell lines of leukemia: HL-60, K-562, MOLT-4, RPMI-8226, and SR, inhibiting their growth from 70% to complete death of cancer cells. Methylfusidate derivative with a spermine fragment was shown to exhibit the widest spectrum of antiproliferative action among the obtained compounds, inhibiting the growth of leukemia, NSC lung cancer, colon cancer, and melanoma cell lines of 68–92%.

Keywords

Triterpenoids Fusidic acid Fusidane amines Antitumor activity 

Notes

Acknowledgements

This work was financially supported by the Russian Foundation of Basic Research (research project No. 17-43-020021 r_a). The part of the research was carried out in accordance with federal program No. АААА-А19-119022290012-3. The structural studies of compounds (3)–(20) were carried out at the Center for Collective Use “Agidel” at the Institute of Petrochemistry and Catalysis, Russian Academy of Sciences. We thank National Cancer Institute for the screening of cytotoxicity of compounds 320.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

44_2019_2445_MOESM1_ESM.pdf (2.9 mb)
Supplementary Information

References

  1. Abdel-Magid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD (1996) Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedure. J Org Chem 61:3849–3862CrossRefGoogle Scholar
  2. Agostinelli E, Arancia G, Vedova LD, Belli F, Marra M, Salvi M, Toniello A (2004) The biological functions of polyamine oxidation products by amine oxidases: Perspectives of clinical applications. Amino Acids 27:347–358CrossRefGoogle Scholar
  3. Bachrach U, Heimer YM (1989) The Physiology of Polyamines. CRC Press, FloridaGoogle Scholar
  4. Boyd MR, Paul KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Res Rep 34:91–109CrossRefGoogle Scholar
  5. Buyel JF (2018) Plants as sources of natural and recombinant anti-cancer agents. Biotechnol Adv 36:506–520CrossRefGoogle Scholar
  6. Cicek-Saydam C, Cavusoglu C, Burhanoglu D, Hilmioglu S, Ozkalay N, Bilgic A (2001) In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid. Clin Microbiol Infect 7:700–702CrossRefGoogle Scholar
  7. Faber V, Dalgleish AG, Newell A, Malkovsky M (1987) Inhibition of HIV replication in vitro by fusidic acid. Lancet 10:827–828CrossRefGoogle Scholar
  8. Gerner EW, Meyskens FL Jr. (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4:781–792CrossRefGoogle Scholar
  9. Gilchrist SE, Lange D, Letchford K, Bach H, Fazli L, Burt HM (2013) Fusidic acid and rifampicin co-loaded PLGA nanofibers for the prevention of orthopedic implant associated infections. J Control Release 170:64–73CrossRefGoogle Scholar
  10. Golledge C (1999) Fusidic acid in other infections. Int J Antimicrob Agents 12:11–15CrossRefGoogle Scholar
  11. Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19:622–638PubMedGoogle Scholar
  12. Kilic FS, Erol K, Batu O, Yildirim E, Usluer G (2002) The effects of fusidic acid on the inflammatory response in rats. Pharm Res 45:265–267CrossRefGoogle Scholar
  13. Kucers A, Bennett NMck (1997) The use of antibiotics. Butterworth–Heinemann, LondonGoogle Scholar
  14. Ni J, Guo M, Cao Y, Lei L, Liu K, Wang B, Lu F, Zhai R, Gao X, Yan C, Wang H, Bi Y (2019) Discovery, synthesis of novel fusidic acid derivatives possessed amino-terminal groups at the 3-hydroxyl position with anticancer activity. Eur J Med Chem 162:122–131CrossRefGoogle Scholar
  15. Loncle C, Salmi C, Letourneux Y, Brunel JM (2007) Synthesis of new 7-aminosterol squalamine analogues with high antimicrobial activities through a stereoselective titanium reductive amination reaction. Tetrahedron 63:12968–12974CrossRefGoogle Scholar
  16. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 65:1866–1879CrossRefGoogle Scholar
  17. Mazumder A, Cerella C, Diederich M (2018) Natural scaffolds in anticancer therapy and precision medicine. Biotechnol Adv 36:1563–1585CrossRefGoogle Scholar
  18. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull KD, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd MJ (1991) Feasibility of a highflux anticancer drug screen using a diverse panel of cultured human tumor cell lines. Nat Cancer Inst 183:757–766CrossRefGoogle Scholar
  19. Reynolds JIF (1996) The extra pharmacopeia. Royal Pharmaceutical Society, LondonGoogle Scholar
  20. Salama AA, AbouLaila M, Moussa AA, Nayel MA, El-Sify A, Terkawi MA, Hassan HY, Yokoyama N, Igarashi I (2013) Evaluation of in vitro and in vivo inhibitory effects of fusidic acid on Babesia and Theileria parasites. Vet Parasitol 191:1–10CrossRefGoogle Scholar
  21. Salimova EV, Mamaev AG, Tretyakova EV, Kukovinets OS, Mavzyutov AR, Shvets KYu, Parfenova LV (2018a) Synthesis and biological activity of fusidic acid cyanoethyl derivatives. Russ J Org Chem 54:1411–1418CrossRefGoogle Scholar
  22. Salimova EV, Mamaev AG, Tretyakova EV, Kukovinets OS, Parfenova LV (2018b) Reductive amination of fusidane triterpenoid ketones. Mediterr J Chem 7:198–203CrossRefGoogle Scholar
  23. Singh K, Espinoza-Moraga M, Njoroge M, Kaur G, Okombo J, De Kock C, Smith PJ, Wittlin S, Chibale K (2017) Synthesis and biological characterisation of ester and amide derivatives of Fusidic acid as antiplasmodial agents. BMC Lett 27:658–661Google Scholar
  24. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JR, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112CrossRefGoogle Scholar
  25. Speck-Planche A (2019) Multiple perspectives in anti-cancer drug discovery: from old targets and natural products to innovative computational approaches. Anti-Cancer Agents Med Chem 19:146–147CrossRefGoogle Scholar
  26. Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58:244–258CrossRefGoogle Scholar
  27. Tripathi VC, Satish S, Horam S, Raj S, lal A, Arockiaraj J, Pasupuleti M, Dikshit DK (2018) Natural products from polar organisms: Structural diversity, bioactivities and potential pharmaceutical applications. Polar Sci 18:147–166CrossRefGoogle Scholar
  28. Tyrrell DA (1969) The possible chemotherapy of respiratory virus diseases. Sci Basis Med Ann Rev 1969:294–319Google Scholar
  29. Woster P, Casero R (2011) Polyamine Drug Discovery. CRC Press, FloridaCrossRefGoogle Scholar
  30. Yatin M (2002) Polyamines in living organisms. J Cell Mol Biol 1:57–67Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Petrochemistry and Catalysis of Russian Academy of SciencesUfaRussian Federation

Personalised recommendations